- Home
- ZNTL vs BYM Comparison
ZNTL vs BYM Comparison
Compare ZNTL & BYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- BYM
- Stock Information
- Founded
- ZNTL 2014
- BYM 2002
- Country
- ZNTL United States
- BYM United States
- Employees
- ZNTL N/A
- BYM N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- BYM Investment Managers
- Sector
- ZNTL Health Care
- BYM Finance
- Exchange
- ZNTL Nasdaq
- BYM Nasdaq
- Market Cap
- ZNTL 238.2M
- BYM 312.7M
- IPO Year
- ZNTL 2020
- BYM N/A
- Fundamental
- Price
- ZNTL $3.12
- BYM $11.77
- Analyst Decision
- ZNTL Buy
- BYM
- Analyst Count
- ZNTL 7
- BYM 0
- Target Price
- ZNTL $10.86
- BYM N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- BYM 60.2K
- Earning Date
- ZNTL 11-04-2024
- BYM 01-01-0001
- Dividend Yield
- ZNTL N/A
- BYM 4.49%
- EPS Growth
- ZNTL N/A
- BYM N/A
- EPS
- ZNTL N/A
- BYM N/A
- Revenue
- ZNTL $40,560,000.00
- BYM N/A
- Revenue This Year
- ZNTL N/A
- BYM N/A
- Revenue Next Year
- ZNTL N/A
- BYM N/A
- P/E Ratio
- ZNTL N/A
- BYM N/A
- Revenue Growth
- ZNTL N/A
- BYM N/A
- 52 Week Low
- ZNTL $2.83
- BYM $9.30
- 52 Week High
- ZNTL $18.24
- BYM $11.77
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- BYM 33.09
- Support Level
- ZNTL $2.92
- BYM $11.91
- Resistance Level
- ZNTL $3.23
- BYM $11.96
- Average True Range (ATR)
- ZNTL 0.17
- BYM 0.07
- MACD
- ZNTL 0.00
- BYM -0.02
- Stochastic Oscillator
- ZNTL 38.33
- BYM 9.70
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. It trust invests in various sectors such as transportation, utilities, health, education, corporate, housing and others.